TrialBritish journal of cancer2013

Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophagogastric cancer: the AGITG ATTAX2 trial.

N C Tebbutt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.